Analysis of Sustained Remission Study and Safety of JAK Inhibitors

The chapter covers a remission study in patients with active disease, showing a high flare rate after treatment cessation, and explores predictors of inactive disease. It also evaluates the safety profile of JAK inhibitors versus TNF and IL-17 inhibitors, revealing no elevated risks in cardiovascular disease, VTEs, or cancer at multiple time points.